Page last updated: 2024-10-31

entinostat and Cutaneous T-Cell Lymphoma

entinostat has been researched along with Cutaneous T-Cell Lymphoma in 2 studies

Research Excerpts

ExcerptRelevanceReference
" The extreme photopotency of UVASens allows the use of lower radiation doses minimising the carcinogenic risks associated with the long-term use of phototherapy."1.40Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells. ( Karagiannis, TC; Sung, JJ; Ververis, K, 2014)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sung, JJ1
Ververis, K1
Karagiannis, TC1
Kato, Y1
Egusa, C1
Maeda, T1
Tsuboi, R1

Other Studies

2 other studies available for entinostat and Cutaneous T-Cell Lymphoma

ArticleYear
Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells.
    Journal of photochemistry and photobiology. B, Biology, 2014, Feb-05, Volume: 131

    Topics: Benzamides; Cell Death; Cell Survival; DNA Damage; DNA Repair; Histone Deacetylase Inhibitors; Human

2014
Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
    Journal of dermatological science, 2016, Volume: 81, Issue:1

    Topics: Acetylation; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Benzoat

2016